Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FUSN

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Key Stats

Today's Range
$21.55
$21.55
50-Day Range
$21.38
$21.55
52-Week Range
$2.31
$21.60
Volume
N/A
Average Volume
1.69 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FUSN Stock News Headlines

Fusion Pharma Stock Price History
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
Fusion Finance Ltd (FUSN)
Fusion Pharma (FUSN) Earnings Dates & Reports
Acquisition of Fusion Pharmaceuticals Completed
See More Headlines

FUSN Stock Analysis - Frequently Asked Questions

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.13. The business had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative trailing twelve-month return on equity of 48.74% and a negative net margin of 4,136.55%.

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
9/19/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FUSN
CIK
1805890
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$94.90 million
Net Margins
-4,136.55%
Pretax Margin
-5,084.07%
Return on Equity
-48.74%
Return on Assets
-36.87%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
10.64
Quick Ratio
10.64

Sales & Book Value

Annual Sales
$2.07 million
Price / Sales
885.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.07 per share
Price / Book
7.02

Miscellaneous

Outstanding Shares
85,060,000
Free Float
78,468,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
-0.69

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:FUSN) was last updated on 9/20/2025 by MarketBeat.com Staff
From Our Partners